Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

News Spotlights Stocks

JNJ: Johnson & Johnson Stock Rises After $8.9Bn Settlement Proposal

post-img

The pharma giant has suggested paying up the sum to thousands of claimants in the span of 25 years.

Johnson & Johnson shares advanced 5% on Wednesday after the company announced it had agreed to pay $8.9bn to tens of thousands of people over 25 years. The pharmaceutical giant has been flooded by lawsuits, claiming its talc powder products caused cancer.
More than 60,000 claimants supported the proposed deal, which is now headed for approval by a bankruptcy court.

If it is given the go-ahead, the settlement will end a legal drama revolving around a carcinogen called asbestos that’s been used in the company’s baby powder for years.


Johnson & Johnson didn’t admit any wrongdoing when it offered to pay up the lofty sum. Erik Haas, J&J’s VP of litigation, said the claims are “specious and lack scientific merit.” In that context, some plaintiffs’ lawyers vowed to pursue a higher compensation package for their clients.

Related Post